Enterohepatic recycling of estrogen after oral administration of 1 mg non-radioactive estriol was studied in ten women taking rifampicin as one of the antitubercular drugs and in fourteen healthy women selected as control subjects. The extent of enterohepatic recycling of estriol (E3) during early follicular phase of menstrual cycle was assessed by monitoring for 48 hours the urinary excretion of its two major metabolites i. e, estriol-16a-glucuronide (E3-16a-G) and estriol-3-glucuronide (E3-3-G). Of these metabolites the former is synthesized in liver as well as in the gut where as later is synthesized exclusively in the gut, hence the change in urinary level of H3-3-G with respect to E3-16a-G was considered to reflect the extent of enterohepatic recycling of E3. The levels of both metabolites in urine were determined by radioimmunoassay. Lower values of variables including E3-3-G output, E3-3-G output as % of the total (E3-16a-G + E3-3-G) excretion and total E3 (E3-16a-G + E3-3-G) output as % dose and the diurnal variation in urinary excretion of these metabolites show that the final elimination of E3 from the body was quicker in these patients as compared with the control subjects, probably due to the reduced extent of enterohepatic recycling of E3 as a result of long term chemotherapy with rifampicin.